Free shipping on all orders over $ 500

GLPG0187

Cat. No. M5241

All AbMole products are for research use only, cannot be used for human consumption.

GLPG0187  Structure
Size Price Availability Quantity
10mM*1mL USD 480  USD480 In stock
1mg USD 133  USD133 In stock
5mg USD 366  USD366 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

GLPG0187 treatment significantly (p < 0.05) reduced PC3 cell number within the metatarsal in vivo and reduced migration (p < 0.05) and proliferation (p < 0.05) but not cell viability in vitro. This new model allows evaluation of the early events of tumour-cell homing and localisation to the bone microenvironment, in addition to determining responses to therapeutic interventions.

Customer Product Validations & Biological Datas
Source Int J Cancer (2015). Figure 3. GLPG0187
Method cell viability, proliferation, migration assay
Cell Lines PC3 cell
Concentrations 50 ng/ml
Incubation Time 96 hr
Results GLPG0187 significantly (p<0.05) reduced the number of tumour cells present in the implanted metatarsal from day 17 on ward
Chemical Information
Molecular Weight 595.71
Formula C29H37N7O5S
CAS Number 1320346-97-1
Solubility (25°C) 10mM in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Li Y, et al, Breast Cancer Res. Genetic depletion and pharmacological targeting of αv integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models.

[2] Reeves KJ, et al. Int J Cancer. Prostate cancer cells home to bone using a novel in vivo model: modulation by the integrin antagonist GLPG0187.

Related Integrin Products
Volociximab

Volociximab (M200) is a chimeric human/murine IgG4 antibody IIA1 targeting integrin α5β1 (EC50=0.2 nM). Volociximab has antiangiogenic and antitumor activities and inhibits the proliferation of human umbilical vein vascular endothelial cells (HUVECs).

GSK 3008348 hydrochloride 

GSK 3008348 hydrochloride is a small molecule integrin αvβ6 antagonist.

HSDVHK-NH2

HSDVHK-NH2 is an antagonist of the integrin αvβ3-vitronectin interaction, with an IC50 of 1.74 pg/mL (2.414 pM).

LDV

LDV, a tripeptide, is a non-fluorescent analog of LDV-FITC.

Cyclo(RADfK)

Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis.

  Catalog
Abmole Inhibitor Catalog




Keywords: GLPG0187 supplier, Integrin, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.